Cape Town-based biomedical engineering startup Impulse Biomedical has raised an undisclosed amount of funding to help it commercialise its products and expand internationally.
Founded by engineering entrepreneurs Giancarlo Beukes and Gokul Nair, Impulse Biomedical is the force behind breakthrough devices that are reshaping emergency care. Their flagship products include the Easy Squeezy, an affordable and easy-to-use asthma inhaler that empowers patients to manage asthma more effectively, and the ZiBiPen, the world’s first reloadable epinephrine auto-injector.
The startup, which secured funding from Futuregrowth back in 2021, has now raised further capital from E Squared Investments and ANZA Capital The funding to enable it to commercialise its products, navigate complex regulatory pathways, and expand internationally in preparation for a Series A capital raise.
“This partnership marks a pivotal step in our journey to deliver accessible, life-saving healthcare at scale,” said Giancarlo Beukes, co-founder of Impulse Biomedical. “With a shared passion for impact, progress and a better tomorrow, we are excited to work with E Squared to place our innovations – present and future – in the hands of people around the world.”
Pyi Maung, head of investments at E Squared, said the company backed scalable ventures that create both commercial value and measurable social impact.
“Impulse Biomedical’s mission and innovation represent the kind of purpose-driven entrepreneurship South Africa and the world needs,” Maung said.
